HTSNUP98-KDM5A-PHD3

Wenwei Lin1, P Jake Slavish1, Aaron H Phillips1

  • 1†Department of Chemical Biology and Therapeutics, ‡Department of Structural Biology, and §Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.

概括

研究人员确定了针对NUP98-KDM5A融合蛋白的新型药物化合物,为治疗预后不佳的儿科急性髓性白血病 (AML) 提供了希望.